Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical – RMB 200 Million Deposit for 14‑Product APAC Commercial Platform
Everest Medicines Limited (HKG: 1952) announced the signing of a letter of intent to acquire...
Hasten Biopharmaceutical
Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
Hasten Biopharmaceutical Co., Ltd. and Everest Medicines Limited (HKG: 1952) announced two strategic agreements: a...
Hasten Biopharmaceutical Accelerates Asia-Pacific Expansion With 11 MAT Transfers
China-based Hasten Biopharmaceutical Co., Ltd, backed by CBC Group, announced the completion of Market Authorization...
Hasten Biopharmaceutical Initiates Phase III Clinical Trial for Lerodalcibep in China
China-based Hasten Biopharmaceutical Co., Ltd, a comprehensive biopharmaceutical company co-established by CBC Group, has announced...
Hasten Biopharmaceutical Gains NMPA Nod for Somatostatin Marketing Rights in China
BEIJING—Hasten Biopharmaceutical Co., Ltd, a biopharmaceutical company supported by the CBC Group, has received approval...
Hasten Biopharmaceutical Expands into Pan-Asia Regions with Celltrion Asset Acquisition
Hasten Biopharmaceutical Co., Ltd, a China-based pharmaceutical company backed by CBC Group, has announced an...
Hasten Biopharmaceutical Secures Licensing Deal for LIB’s Lerodalcibep in Greater China
China-based Hasten Biopharmaceutical Co., Ltd has entered into a licensing agreement with US firm LIB...
Hasten Biopharm Acquires Commercial Rights to Rocephin in China from Roche
China-based Hasten Biopharmaceutical Co., Ltd has announced the acquisition of the commercial rights in China...
Hasten Biopharmaceutical Secures $315 Million Investment for Pipeline Expansion
China-based Hasten Biopharmaceutical Co., Ltd has reportedly received USD 315 million in a fundraising round...